RIBER AFFICHE UNE PROGRESSION DE SES RÉSULTATS AU PREMIER SEMESTRE 2026

RIBER reported H1 2026 revenue of €12.7M, up 19% year on year, and returned to profitability with net income of €0.2M versus a €0.8M loss in H1 2025; gross margin expanded 360bps to 39.8%. Services and accessories revenue rose 71% to €5.1M, while the company secured €6.0M in bank financing to industrialize its ROSIE II photonics platform. The €26.8M order backlog fell 3%, constrained by Asian export restrictions that prevented conversion of more than €8M of orders; RIBER expects 2026 revenue roughly in line with 2025, conditional on obtaining an export license.

Analysis

ALRIB’s earnings quality is improving through a richer aftermarket mix, which should carry higher repeatability and lower working-capital volatility than one-off system shipments. However, the equity’s near-term rerating remains constrained by a shrinking system backlog and elongated customer approvals: the market will likely value the service growth at a lower multiple until system order intake reaccelerates. The unaudited interim accounts also reduce confidence in extrapolating the small operating profit.

The key swing factor over the next 1-3 months is export-license resolution, not semiconductor end-demand. A favorable decision would unlock delayed conversion and potentially restore utilization visibility; a further delay turns the nominally stable full-year outlook into a revenue-recognition and inventory/cash-conversion risk. The new borrowing changes the company from modest net cash to net debt before ROSIE II has demonstrated commercial returns, so execution slippage could pressure equity value disproportionately in a small-cap liquidity event.

ROSIE II offers 6-18 month option value, but investor enthusiasm should be discounted until independent milestones appear: repeat customer orders, paid wafer volumes, process-yield data, and a defined unit economics model. The quantum/photonics customer set is still predominantly pre-volume; QUBT is not a direct read-through, and NVO’s foundation-linked quantum program does not create a meaningful earnings linkage for NVO. A more plausible second-order beneficiary of oxide-on-silicon adoption would be broader silicon-photonics supply chains, but ALRIB must first prove it can move from bespoke equipment to reproducible production tools.

Contrarian view: the market may overreact positively to the financing as validation. Debt funds capacity, not demand, and the dividend-like capital distribution immediately before a leverage increase weakens balance-sheet optionality. Conversely, if the export authorization lands and service sales remain elevated, consensus may be underestimating the incremental gross-margin conversion from a larger installed base.

Key Decisions for Investors

• Maintain ALRIB as a watch-list long rather than chase the initial result-driven move; initiate only after export-license confirmation or a disclosed system-order recovery. Target a 6-12 month position sized for small-cap liquidity risk, with thesis invalidated by another guidance reduction or system backlog falling below €15m.
• For an existing ALRIB long, use the Q4 2026 ROSIE wafer-sample milestone as a binary de-risking checkpoint, not a commercialization catalyst. Add only if RIBER discloses qualified customer demand, pricing, and repeatable production performance; otherwise treat ROSIE as R&D-funded optionality.
• Avoid using QUBT or NVO as hedges or sympathy trades: neither has sufficiently direct revenue exposure to ALRIB’s equipment cycle. If a quantum-theme hedge is required, use a diversified quantum/advanced-computing basket rather than a single-name pair.
• Monitor net debt, operating cash flow, and inventory at FY2026 results in February 2027. A material increase in net debt without corresponding backlog conversion would warrant reducing ALRIB exposure even if reported revenue meets guidance.